Fulvestrant 500 mg Versus Anastrozole 1 mg for the First- ...
Fulvestrant 500 mg showed improved overall survival (OS) over anastrozole in first-line treatment for ER-positive advanced breast cancer, with a 30% mortality risk reduction. Median OS was 54.1 vs. 48.4 months. Safety profiles were similar, and the OS benefit was consistent across subgroups. The phase III FALCON trial may confirm these findings.
Related Clinical Trials
Reference News
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First- ...
Fulvestrant 500 mg showed improved overall survival (OS) over anastrozole in first-line treatment for ER-positive advanced breast cancer, with a 30% mortality risk reduction. Median OS was 54.1 vs. 48.4 months. Safety profiles were similar, and the OS benefit was consistent across subgroups. The phase III FALCON trial may confirm these findings.